With five therapies already approved by the Food and Drug Administration, and with more than 60 in development, the term “biosimilars” will be seen and heard much more frequently in the U.S. health care system throughout the next decade.
Over the past several decades, medical innovation has unlocked the power of biologics — scientifically complex therapies used to treat diseases such as rheumatoid arthritis, ulcerative colitis, psoriasis, and several forms of cancer.
Information never stops. We help you start your day by making sense of it all. Over 150,000 government and industry executives rely on Morning Consult to stay informed. Our original reporting and morning email briefings make it possible for you to know everything you need to know, every day, at the intersection of Wall Street and business strategy, policy and politics.